Skip to Main Content

Loxo Oncology (LOXO) chief executive Dr. Joshua Bilenker negotiated the $8 billion sale of his company to Eli Lilly (LLY) in little more than two weeks, and did not approach any other suitors or engage in a bidding war.

According to a new filing with the Securities and Exchange Commission, Loxo believed that its most valuable asset was not its approved medicine, Vitrakvi, but an experimental one, the RET inhibitor LOXO-292.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Thanks for making your insonin so i can live.however it is so expensive it is a hardship. Their have been times i did not have money and had to be in hospital wondering if i would live. Now still stressed every month if i will be able to buy my insulin. it sucks to be at the mercy of big pharma.

Comments are closed.